2Bonow R O,Carabello B A,Chatterjee K,et al.ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons[J].J Am Coll Cardiol, 2006,3(48):e1-e148.
3Camm A J,Kirchhof P,Lip G Y H,et al.Guidelines for the management of atrial fibrillation:the task force for the management of atrial fibrillation of the European Society of Cardiology(ESC)[J].Eur Heart J, 2010,19(31):2369-2429.
5Ansell J,Hirsh J,Hylek E,et al.Pharmacology and management of the vitamin K antagonists:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines(8th Edition)[J].Chest, 2008,6 Suppl(133):160S-198S.
6Ansell J,Hirsh J,Poller L,et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 Suppl):204s-233s.
7Miners JO,Birkett DJ.Cytochrome P4502C9:an enzyme of major importance in human drug metabolism[J].Br J Clin Pharmacol,1998,45(6):525-538.
8Scordo MG,Pengo V,Spina E,et al.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Clin Pharmacol Ther,2002,72(6):702-710.
9Palkimas MP,Skinner HM,Gandhi PJ,et al.Polymorphism induced sensitivity to warfarin:a review of the literature[J].J Thromb Thrombolysis,2003,15(3):205-212.
10Furuya H,Fernandez-Salguero P,Gregory W,et al.Gennetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy[J].Pharmacogenetics,1995,5(6):389-392.
2Liu Xia, Ling ZongXin, Li LanJ uan, et al. Invasive fungal infec- tions in liver transplantation[J]. Int J Infect Dis, 2011,15 ( 5 ) e298-e304.
3Zhang ShiMin,Pillai V C,Mada S R,et al. Effect of voricon- azole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes[J]. Xeno- biotica,2012,42 (5) :409-416.
4Jacobs F,Selleslag D,Aoun M,et al. An observational efficacy and safety analysis of the treatment of acute invasive aspergil- losis using voriconazole[J]. Eur J Clin Microbiol Infect Dis, 2012,31(6) :1173-1179.
